Fig. 5: HY-N0022 inhibits HCC sorafenib resistance and tumor progression by targeting PDHB. | Communications Biology

Fig. 5: HY-N0022 inhibits HCC sorafenib resistance and tumor progression by targeting PDHB.

From: Isoacteoside alleviates hepatocellular carcinoma progression by inhibiting PDHB-mediated reprogramming of glucose metabolism

Fig. 5

A Computer Virtual Docking Combination of Isoacteoside and PDHB. B Binding site of Isoacteoside to PDHB. C WB were used to detect the effects of Isoacteoside on PDHB expression in HCC cells. D, H Cytotoxicity assay was used to detect the IC50 of HepG2 and SMMC7721 after HY-N0022 treatment. E, I The effect of HY-N0022 on sorafenib resistance of HCC was detected. F, J CCK8 analysis was used to detect the effect of HY-N0022 on HCC cell proliferation. G, K Transwell assay was used to detect the effect of HY-N0022 on the invasion ability of HCC cells. Scale bar = 200 μm. L, O RT-PCR to detect the effect of HY-N0022 on the EMT ability of HCC cells. M, N, P, Q The effects of HY-N0022 on tumor growth was evaluated in vivo. R, S RT-PCR was used to detect the effects of HY-N0022 treatment on PDHB and glycolysis-related genes. Data are presented as means ± standard deviation from three independent experiments; *P < 0.05, **P < 0.01, ***P < 0.001.

Back to article page